Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project

Knoll, Maria Deloria; Bennett, Julia C.; Garcia Quesada, Maria; Kagucia, Eunice W.; Peterson, Meagan E.; Feikin, Daniel R.; Cohen, Adam L.; Hetrich, Marissa K.; Yang, Yangyupei; Sinkevitch, Jenna N.; Ampofo, Krow; Aukes, Laurie; Bacci, Sabrina; Bigogo, Godfrey; Brandileone, Maria-Cristina C.; Bruce, Michael G.; Camilli, Romina; Castilla, Jesús; Chan, Guanhao; Chanto Chacón, Grettel; ... (2021). Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project. Microorganisms, 9(4) MDPI 10.3390/microorganisms9040742

[img]
Preview
Text
microorganisms-09-00742.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute for Infectious Diseases > Research
04 Faculty of Medicine > Service Sector > Institute for Infectious Diseases > Clinical Microbiology
04 Faculty of Medicine > Service Sector > Institute for Infectious Diseases > Bacteriology

UniBE Contributor:

Hilty, Markus

Subjects:

500 Science > 570 Life sciences; biology

ISSN:

2076-2607

Publisher:

MDPI

Language:

English

Submitter:

Markus Hilty

Date Deposited:

10 Nov 2021 11:26

Last Modified:

10 Nov 2021 11:28

Publisher DOI:

10.3390/microorganisms9040742

PubMed ID:

33918127

Uncontrolled Keywords:

global; invasive pneumococcal disease; pneumococcal conjugate vaccines; pneumococcal meningitis; surveillance.

BORIS DOI:

10.48350/160012

URI:

https://boris.unibe.ch/id/eprint/160012

Actions (login required)

Edit item Edit item
Provide Feedback